Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Cilengitide trifluoroacetate

For research use only.

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

42 publications

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 454 In stock
USD 270 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cilengitide trifluoroacetate has been cited by 42 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Biological Activity

Description Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Targets
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. [1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. [2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. [3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. [4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
G28 NYnwe3JuTnWwY4Tpc44hSXO|YYm= NVjUeIY1PTBizsznM41t NXzre3hWOzBxNkCvNVIxKG2rbh?= M{X0OYlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBHSUtuIGPyZ{BidmRiQXv0 NVT4dpYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1  M1e4WGZ2dmO2aX;uJGF{e2G7 NIfLOowzOC92MD:2NEDPxGdxbXy= NXLqS|ZYcW6qaXLpeJMhTkGNIHHu[EBUemQEoB?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G44 NEXKVldCeG:ydH;zbZMhSXO|YYm= NYq5bVNqOS93L{WwJO69\y:vbB?= NWXtWlB7OjRiaB?= NFq0XmtqdmS3Y3XzJIFxd3C2b4Ppdy=> NHruOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 NEiwWnZCeG:ydH;zbZMhSXO|YYm= NVjZZVFWOS93L{WwJO69\y:vbB?= MX6yOEBp MVHpcoR2[2W|IHHwc5B1d3Orcx?= Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G44 Mk\5VJJwdGmoZYLheIlwdiCDc4PhfS=> NH61N24yNzVxNUCg{txoN22u MWOyOE81QC95MjDo MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NH\iW3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 M3;GTHBzd2yrZnXyZZRqd25iQYPzZZk> M4rL[VEwPS93MDFOwIcwdWx? NYewTIVGOjRxNEivO|IhcA>? NWfDO3ZmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{XOblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1  NEPwb2NCeG:ydH;zbZMhSXO|YYm= M163U|EwPS93MDFOwIcwdWx? NEnETFUzPCCq MWXpcoR2[2W|IHHwc5B1d3Orcx?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
HMEC-1  NFrQNYpRem:uaX\ldoF1cW:wIFHzd4F6 NV3wc2pOOS93L{WwJO69\y:vbB?= M4nqS|I1NzR6L{eyJIg> M3foOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NYT4U2FxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1  MYfGeY5kfGmxbjDBd5NigQ>? NILrWocyNzVxNUCg{txoN22u NFX0eHIzPCCq M2rzSIlv\HWlZYOgZUBld3OnIHTldIVv\GWwdDDk[ZRi[2ivZX70xsA> MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
LNT-229  M{X2O2Z2dmO2aX;uJGF{e2G7 NGfoZmUxNjFxMT:xNEDPxE1? NYjHN2E4OjRiaB?= NVXIcWR{cW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
T98G MVXGeY5kfGmxbjDBd5NigQ>? MYKwMlEwOS9zMDFOwG0> MYiyOEBp NIPEUm1qdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO|E9N2F-
LN-18 NH[2[o1HfW6ldHnvckBCe3OjeR?= MW[wMlEwOS9zMDFOwG0> NVnSWIY4OjRiaB?= NULwPGM{cW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVjFb4d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
LN-308 MkTTSpVv[3Srb36gRZN{[Xl? M3rXTlAvOS9zL{GwJO69VQ>? M4fCO|I1KGh? MULpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NH\4e|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
U87MG NVfqWI9JTnWwY4Tpc44hSXO|YYm= MortNE4yNzFxMUCg{txO Ml3UNlQhcA>? Mn\RbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
U87  NFfqUWJHfW6ldHnvckBCe3OjeR?= MWewMVI2KM7:Zz;tUC=> NID4bocyOiCqwrC= MmLTbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251 MUHGeY5kfGmxbjDBd5NigQ>? MYCwMVI2KM7:Zz;tUC=> NG\4WYoyOiCqwrC= NUHrXFU3cW6mdXPld{BifXSxcHjh[5kh\G:|ZTDk[ZBmdmSnboTsfS=> M4nJNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U87  MXTBdI9xfG:|aYOgRZN{[Xl? M1jseVI2KM7:Zz;tUC=> NIjQT2MzPC92ODDo MkDhbY5lfWOnczDhdI9xfG:|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6 M4PIWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U251 NHrONmFCeG:ydH;zbZMhSXO|YYm= NEfDe4ozPSEQvHevcWw> NEjNdFczPC92ODDo Mk\JbY5lfWOnczDhdI9xfG:|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6 M{TD[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U87  M4Hqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjkZm9QOC1{NTFOwIcwdUx? MVWwMVQ5KGh? MlzvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NUKxOYU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U251 NWXTTWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfWNE0zPSEQvHevcWw> M1Hhd|AuPDhiaB?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M13yPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U251MG MXzBdI9xfG:|aYOgRZN{[Xl? M2P5b|EhyrWP NEfCTlc1QCCq NF;FeGxqdmS3Y3XzJIFxd3C2b4Ppdy=> MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U87MG M13BZWFxd3C2b4Ppd{BCe3OjeR?= Mmf6NUDDvU1? MUi0PEBp M4HrN4lv\HWlZYOgZZBweHSxc3nz M2\vflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U251MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMVI2KM7:TR?= NV7wdIxTOjRxNEigbC=> MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NUS4NFcoRjJ|M{W0PFA4RC:jPh?=
U87MG M3rQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTYdVM6OC1{NTFOwG0> MlXFNlQwPDhiaB?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NX;QUlR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVQ5ODdpPkKzN|U1QDB5PD;hQi=>
MCF-7  M3HZdmFxd3C2b4Ppd{BCe3OjeR?= MVOwMVIxKM7:TR?= NFnNOmE1QCCq NF23NlZqdmS3Y3XzJIFxd3C2b4Ppdy=> NH\wOVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1N|ExOid-MkSxOVMyODJ:L3G+
T-47D MofjRZBweHSxc3nzJGF{e2G7 MUmwMVIxKM7:TR?= MnPuOFghcA>? NEf0PGJqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
MCF-7  NGjTfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDNXGRFOC1{MDFOwG0> NHjSc2U6PiCq NUL5RYFQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
T-47D MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHwZm1nOC1{MDFOwG0> MnTqPVYhcA>? NXTxeJFGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEPCU2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1N|ExOid-MkSxOVMyODJ:L3G+
FaDu  NX\a[2dDSXCxcITvd4l{KEG|c3H5 MYWyOeKhyrWPwrC= MXW0POKhcMLi NXjDfnhZcW6mdXPld{BieG:ydH;zbZM> NHvZ[GQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
CAL27 MmfSRZBweHSxc3nzJGF{e2G7 NVTW[VVROjYEoNM1UeKh M1fV[VQ5yqCqwrC= MYrpcoR2[2W|IHHwc5B1d3Orcx?= MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
SCC25 NG\NfGNCeG:ydH;zbZMhSXO|YYm= MUSyOeKhyrWPwrC= M{TuUVQ5yqCqwrC= MmfIbY5lfWOnczDhdI9xfG:|aYO= Ml74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
FaDu  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkRZQ3NjJ34pETNlAxyqEEtV2= NFSyWmc4OiCq NULUenJYemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= NEDoNXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
CAL27 M{TYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq2MlI26oDVMkCwxsDDvU1? M332W|czKGh? Ml7RdoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25? NX;qSFlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
SCC25 NYf4TIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;2Ok4zPeLCk{KwNOKhyrWP MXy3NkBp NE[xU4Jz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NHPlTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O|A2Pid-MkS1OVcxPTZ:L3G+
H28 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGrwPY8yKG6PLUKwNEDPxE1? MWq3NkBp MojY[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NX7vNJJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
MM05 MnX3R4VtdCCYaXHibYxqfHliQYPzZZk> M1HH[FEhdk1vMkCwJO69VQ>? NH;ndlM4OiCq MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1zndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
MSTO-211H NXH6e3ZsS2WubDDWbYFjcWyrdImgRZN{[Xl? NEnpVJgyKG6PLUKwNEDPxE1? M2X5d|czKGh? NHz2XXpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NV7I[FZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
REN MnyzR4VtdCCYaXHibYxqfHliQYPzZZk> M{HBXlEhdk1vMkCwJO69VQ>? MYq3NkBp NXjENIg5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUK3OEc,OjR3OUWyO|Q9N2F-
LN-308  MlvySpVv[3Srb36gRZN{[Xl? Moe5NVDjiIoQvH2= MnL1NlQhcA>? MWrEUXNQyqB? M4\yWZJm\HWlZYOgRYhTKHC{b4TlbY4hdGW4ZXzzJIFv\CCGUlWgdoVxd3K2ZYKgZYN1cX[rdIm= NXHPUZVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
HaCaT  MoPXSpVv[3Srb36gRZN{[Xl? NXP3WIh[OTEkgJpOwI0> NIjLNI81QCCq MnTuSG1UV8Li NGH1OYxz\WS3Y3XzJHRITi4QskNCpI1TVkFiZYjwdoV{e2mxbh?= M{HneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
S-24 MnfhSpVv[3Srb36gRZN{[Xl? NVPme25vOS9zMPMAje69dQ>? MXWyOEBp M3LoR2ROW00EoB?= MYny[YR2[2W|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=> M1\LcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
ZH-161 Ml;sSpVv[3Srb36gRZN{[Xl? M3e0XlEwOTEkgJpOwI0> M3TrPVI1KGh? Mk[0SG1UV8Li Mn;vdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJk> NGLxVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
LN-308  Mnv5SpVv[3Srb36gRZN{[Xl? Ml3xNU8yOC9zMEFihKnPxG1? NXPKcGVYOjRiaB?= MXzEUXNQyqB? MlrhdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NW\IRohsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
M21 M{XCcWZ2dmO2aX;uJIF{e2G7 MnLMNUBpeg>? MnnlRolv\GmwZzDh[oZqdmm2eTD0c{BqdnSnZ4LpckBidHCqYY[vZoV1[TNiaHX0[ZJw\GmvZYKgbY4hcHWvYX6gUVIyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51\We{aX6tcYVlcWG2ZXSgbJVu[W5iTUKxJINmdGxiYXTo[ZNqd25idH:geol1em:wZXP0bY4h[W[2ZYKgNUBpeiCrbjDwdoV{\W6lZTDv[kBOdkOuMjygTWM2OCB;IECuNFAxPCEQvF2u M4nTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{WzPFE1Lz5{Nke1N|gyPDxxYU6=
HEK293T NIDZWHBHfW6ldHnvckBie3OjeR?= MlrXNkBpenN? NF\O[XFDcW6maX7nJIFn\mmwaYT5JJRwKHOxbIXicIUhfHK3bnPheIVlKGi3bXHuJJJm[2:vYnnuZY51KE[lLYTh[4dm\CCjbIDoZXZj\XSjMzDhcoQhcW62ZXfybY5{KHencnWg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgZYZ1\XJiMjDodpMh[nliY3;tdIV1cXSrb36gSWxKW0FvbHnr[UBie3OjeTygTWM2OCB;IECuNFAxPTFizszNMi=> MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUWwPVYoRjJ2MEm1NFk3RC:jPh?=
HT-29 MWrGeY5kfGmxbjDhd5NigQ>? NWTtOo1ROiCqcoO= Mk[wRY51[WexbnnzeEBi[3Srdnn0fUBifCCrboTl[5JqdiCjbIDoZXZj\XSjNTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAzKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF{IN88UU4> M4r4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
HEK293 NHi2O5RHfW6ldHnvckBie3OjeR?= NHzqeJczKGi{cx?= MXrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF|IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDh[Ihme2mxbjD0c{BncWK{aX7v[4VvKGGodHXyJFIhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=> Ml;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
SKOV3 NHrpSIZHfW6ldHnvckBie3OjeR?= MUiyJIhzew>? M3Gw[2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaX70[YdzcW5iYXzwbIFX[mW2YUPhcJBp[V[kZYThOUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBi\Ginc3nvckB1dyCoaXLybY5w\2WwIHHmeIVzKDJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{eg{txONg>? NVjQTpRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N|UyPTl2PD;hQi=>
U87MG NHzLXHNHfW6ldHnvckBie3OjeR?= NHXP[osyODBibl2= NF\pfZIzPCCqcoO= NIHT[5FKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJA2OyCjY3P1cZVt[XSrb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k NV7CZolsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NETZRXBHfW6ldHnvckBie3OjeR?= NUDBN2pPOTByIH7N NUD5RpQ2OjRiaILz MYLJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bi[2O3bYXsZZRqd25iYYSgNVAxKG6PIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k NFn5NZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG MX3GeY5kfGmxbjDhd5NigQ>? NIPpPVQyODBibl2= NFL0OZYzPCCqcoO= NVvvZXNHUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBxPTNiYXPjeY12dGG2aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG MYHGeY5kfGmxbjDhd5NigQ>? NIHae|IyODBibl2= NHLYXZE5KGi{cx?= MWHJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIF3EUVIhdVKQQTDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjC4JIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCUVD3QR3IhdWW2aH;k MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NHfjfWNHfW6ldHnvckBie3OjeR?= NXnMOmdVOTByIH7N MVyyOEBpenN? NG[xZ|FKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJI1mfGixZB?= Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NVPYd2JGTnWwY4Tpc44h[XO|YYm= M2nx[|ExOCCwTR?= MnPINlQhcHK| M3XyeWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BjgSCUVD3QR3IhdWW2aH;k NILOZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG NFjGfZRHfW6ldHnvckBie3OjeR?= MmTiNVAxKG6P M3zK[FI1KGi{cx?= MmPITY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliUmStVGNTKG2ndHjv[C=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG NVHhfFh1TnWwY4Tpc44h[XO|YYm= Moq5NVAxKG6P MVSyOEBpenN? M3POZWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BidmRiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG M4PsXmZ2dmO2aX;uJIF{e2G7 MWixNFAhdk1? M3nKeVI1KGi{cx?= Mo\BTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwNlEhdVKQQTDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>? NXT4Vmk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG MkjyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFHMR2EyODBibl2= MUi3NkBpenN? NHiyTVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyMDDuUUBi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZpkhVVSVIHHzd4F6 MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG NVPsWJZCSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1rzV|ExOCCwTR?= MmXoO|IhcHK| M4WxW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZZQhOTByIH7NJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCPVGOgZZN{[Xl? NVLYU2k6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NFnhPY1E\WyuIHP5Z4xmKGG|c3H5 NILYfHgyODBibl2= MmiyNlQhcHK| NFrMTXVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZZQhOTByIH7NJIFnfGW{IEK0JIhzew>? NWXKN2RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NFy1SWxCdnSrLXnueoF{cX[nIHHzd4F6 MXOxNEB2VQ>? NUDm[4Y4OjRiaILz NGW1ZYdCdnSrLXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTD0doFve3enbHygZZN{[Xl? NX3y[pF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NILoSW9CdnSrLXnueoF{cX[nIHHzd4F6 M2LPfFExKHWP M1PkR|I1KGi{cx?= M4DWVWFvfGlvaX72ZZNqfmViYXP0bZZqfHliaX6gbJVu[W5iVUi3UWch[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KHS{YX7ze4VtdCCjc4PhfS=> M2DEdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
In vivo Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). [5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. [6]

Protocol

Kinase Assay:[2]
- Collapse

Integrin-binding competition assay:

Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:[3]
- Collapse
  • Cell lines: Human microvascular endothelial cell line HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 days
  • Method: HMEC-1 (1×104 per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Human glioblastoma xenografts U87 MG
  • Dosages: 100μg
  • Administration: Daily i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 702.68
Formula

C29H41F3N8O9

CAS No. 199807-35-7
Storage powder
in solvent
Synonyms EMD 121974, NSC 707544
Smiles CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • Answer:

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • Question 2:

    Is Cilengitide a TFA salt?

  • Answer:

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Integrin Signaling Pathway Map

Tags: buy Cilengitide trifluoroacetate | Cilengitide trifluoroacetate supplier | purchase Cilengitide trifluoroacetate | Cilengitide trifluoroacetate cost | Cilengitide trifluoroacetate manufacturer | order Cilengitide trifluoroacetate | Cilengitide trifluoroacetate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID